I am a
Home I AM A Search Login

Papers of the Week


Papers: 9 Apr 2022 - 15 Apr 2022


Pharmacology/Drug Development


2022 Apr 09


J Headache Pain


23


1

Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).

Authors

Barbanti P, Egeo G, Aurilia C, d'Onofrio F, Albanese M, Cetta I, Di Fiore P, Zucco M, FilippiBonassi M, Bono F, Altamura C, Proietti S, Bonassi S, Vernieri F
J Headache Pain. 2022 Apr 09; 23(1):46.
PMID: 35397503.

Abstract

Fremanezumab has demonstrated to be effective, safe, and tolerated in the prevention of episodic or chronic migraine (CM) in randomized, placebo-controlled trials (RCTs). Real-life studies are needed to explore drug effects in unselected patients in routine circumstances and to provide higher generalizability results. This study explores the effectiveness, safety, and tolerability of fremanezumab in a real-life population of individuals affected by high-frequency episodic (HFEM: 8-14 days/month) or CM.